Alan Grosset - Academia.edu (original) (raw)

Papers by Alan Grosset

Hematology (Amsterdam, Netherlands), 2000

Twenty-five patients with a diagnosis of myelodysplastic syndromes (MDS) were randomized to eithe... more Twenty-five patients with a diagnosis of myelodysplastic syndromes (MDS) were randomized to either begin therapy with pentoxifylline, ciprofloxacin and dexamethasone (PCD) immediately (10 patients) or after a 12 week observation period (control arm, 15 patients). PCD was administered with the goal of suppressing cytokine-induced excessive intramedullary apoptosis of hematopoietic cells. No marked fluctuations of blood counts were noted during the period of observation. Twenty-two patients completed at least 12 weeks of therapy: 18/22 showed some type of hematologic response, 9/18 showing an improvement in absolute neutrophil count only (p = < 0.001) and 9/18 showing multi-lineage responses. No unique category of MDS responded better, however 19/25 patients had refractory anemia (RA)/RA with ringed sideroblasts. The median time to response was 6 weeks and 3/18 responding patients maintained their responses beyond a year. We conclude that hematologic improvement in response to PCD ...

Journal of pain and symptom management, 2005

Two multicenter, randomized, double-blind, crossover studies with identical designs evaluated the... more Two multicenter, randomized, double-blind, crossover studies with identical designs evaluated the efficacy of oral extended-release hydromorphone (HHER) administered q24h compared with immediate-release hydromorphone (HHIR) dosed four times daily in patients with persistent moderate to severe pain. Patients titrated to a stable HHER dose were randomized to individualized doses of HHER or HHIR for 3 to 7 days before crossover to the second treatment. Primary efficacy end point was the mean of average pain intensity (API) scores, rated on a 0-to 10-point numeric scale, over the last 2 days before the pharmacokinetics/pharmacodynamics day of each double-blind period. Difference between treatments (HHER Ϫ HHIR) in study 1 was 0.17 with a 90% confidence interval (CI) (Ϫ0.01, 0.34); in study 2, difference was 0.07 with a 90% CI (Ϫ0.12, 0.26). There were no significant differences between treatments in API scores or amount of rescue medication used at any time interval within the 24-hour dosing period. No reduction in pain control occurred in patients administered HHER at the end of the 24-hour dosing period. Most treatment-emergent adverse events were opioid-related. In these studies, HHER administered q24h and HHIR dosed four times daily provided comparable analgesia at an equivalent total daily dose. J Pain Symptom Manage 2005;29:584-594. Ć 2005 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Thrombosis Research, 1997

there is a clinical failure rate of up to 10YO. Newer treatment strategies include low-molecular-... more there is a clinical failure rate of up to 10YO. Newer treatment strategies include low-molecular-weight heparins (LMWH). As part of an international study comparing the efficacy and safety of enoxaparin, a LMWH versus UFH in patients with venous thromboembolism, we studied the effects of enoxaparin and UFH on the plasma concentrations of two activation peptides, fragment 1 + 2 (FI + 2), and thrombin-antithrombin Ill (TAT) complexes.

Journal of Pain and Symptom Management, 2005

Journal of pain and symptom management, 2005

American Journal of Hematology, 1994

Patients who require oral anticoagulation usually receive warfarin. We used an indanedione drug, ... more Patients who require oral anticoagulation usually receive warfarin. We used an indanedione drug, anisindione, in two patients who were intolerant of warfarin but who needed long-term oral anticoagulation. The use of this alternative oral anticoagulant is reviewed.